Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive JNJ-40411813 for major depressive disorder with anxiety symptoms
2011-006121-26Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing JNJ-40411813 adjunctive treatment with Placebo adjunctive treatment (2 arms). Primary endpoint: Change from baseline in HAM-A6 score to 4-week endpoint. Started Apr 2012; status: completed.
02
Drugs
adx-71149
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-006121-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006121-26.